Tocilizumab en artritis reumatoide
Tài liệu tham khảo
Pablos Álvarez, 2009, La interleucina 6 en la fisiopatología de la artrirtis reumatoide, Reumatol Clin., 5, 10.1016/S1699-258X(09)70203-7
Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum., 54, 2817, 10.1002/art.22033
Nishimoto, 2009, Mod Rheumatol., 19, 12, 10.1007/s10165-008-0125-1
Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab, Ann Rheum Dis., 66, 1162, 10.1136/ard.2006.068064
Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial, Lancet., 371, 989, 10.1016/S0140-6736(08)60453-5
Kremer, 2008, Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study, Arthritis Rheum., 589, L11
Genovese, 2008, Arthritis Rheum., 58, 2968, 10.1002/art.23940
Emery, 2008, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial, Ann Rheum Dis., 67, 516, 10.1136/ard.2008.092932
Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis., 69, 88, 10.1136/ard.2008.105197
Rubbert-Roth, 2009, Interim Results of the TAMARA Study Effectiveness and Safety of the Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab After 4 and 24 Weeks in Patients with Active Rheumatoid Arthritis (RA) [abstract], Arthritis Rheum., 60, 412
Bykerk, 2010, Tocilizumab in patients with rheumatoid arthritis and an inadequate response to dmards and/or tnf inhibitor therapy: ACT-SURE preliminary results, Ann Rheum Dis., 69, 379
Smolen, 2010, Efficacy of tocilizumab in patients with ra and inadequate response to DMARDs or TNF inhibitors: up to 3.5-year data from ongoing extension studies, Ann Rheum Dis., 69, 386
Jones, 2010, Efficacy of Tocilizumab in patients with rheumatoid arthritis who had never been exposed to or had never failed methotrexate: analysis of up to 3 years of treatment in a long-term extension study, Ann Rheum Dis., 69, 386
Smolen, 2008, Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials, Arthritis Rheum., 589 Suppl, 1669
Van Vollenhoven, 2010, Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 2.6 years of treatment in long-term extension studies, Ann Rheum Dis., 69, 544